A novel lipoprotein (a) lowering drug, D-47, decreases neointima thickening after vascular injury

Yutaka Nakaya1, Daiju Fukuda2, Takashi Oyamada1, Kazuo Ogawa3, Nagakatsu Harada1, Hironori Nakagami4, Ryuichi Morishita5, Masataka Sata2, and Hiroshi Sakau1

1Department of Nutrition and Metabolism, and 2Department of Cardiology, Institute of Biomedical sciences, Tokushima University Graduate School, Tokushima, Japan, 3Pharmaceutical Science, Tokushima Bunri University, Tokushima, Japan and 4Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Osaka, Japan

Abstract: Although Lp(a) have been thought to be a cardiovascular risk factor, it is unclear whether lowering Lp(a) levels reduces the risk of cardiovascular diseases. No pharmacological agents which selectively reduce serum Lp(a) levels, and Lp(a) is present in primate but absent in common laboratory animals such as mice and pigs. In the present study we used transgenic mice of human Lp(a) and tested effect a novel Lp(a) lowering drug D-47 on neointima formation after vascular injury. D-47 successfully decreased plasma levels of Lp(a) and possibly inhibited neointima formation in Lp(a) transgenic mice. The results indicate that we can modulate plasma Lp(a) levels by pharmacologic agents and inhibit atherogenic properties of Lp(a) by reducing plasma levels of Lp(a). J. Med. Invest. 64: 64-67, February, 2017

Keywords: lipoprotein a, atherosclerosis, cardiovascular events, low density lipoprotein

INTRODUCTION

Lipoprotein(a) [Lp(a)] is composed of a low density lipoprotein (LDL) particle with apolipoprotein (a) [apo(a)]. Apo(a) is a homolog of plasminogen that contains 10 different types of plasminogen kringle-4-like repeats (kringle-4 types 1 through 10), suggesting its relation to anti-fibrinolytic properties. Many studies have shown elevated plasma Lp(a) levels as a risk factor for a variety of atherosclerotic and thrombotic diseases including peripheral vascular disease, thromboembolism, and coronary heart disease (1, 2). According to the Adult Treatment Plan (ATP) III guidelines (3), Lp(a) was classified as an “emerging” risk factor for cardiovascular disease. Plasma levels of Lp(a) are under genetic control and there is no specific agent to reduce plasma Lp(a). Lipid-lowering agents, statins, have little or no effect on plasma Lp(a) levels. Niacin and estrogen reduce plasma Lp(a) levels, but only slightly. In addition to lowering Lp(a), niacin has lowering effects on LDL-cholesterol, triglycerides and remnant cholesterol levels. Thus, the benefit of niacin on CVD cannot be mediated only by Lp(a) reduction. Therefore, highly specific and potent Lp(a) lowering drugs are awaited to clarify the Lp (a) function.

It is challenging to prove that Lp(a) lowering can reduce cardiovascular risk in patients with high Lp(a) levels as well as in animal models. To prove drug effect on Lp(a) and its function, however, the use of animal models is difficult because of the unusual species distribution of Lp(a). Lp(a) is only present in humans and primates, and is absent in common laboratory animals such as mice and pigs (4). In the present study we used double transgenic mice of human Lp(a), and studied a novel Lp(a) lowering drug on vascular injury models to study atherogenic action of Lp(a).

METHODS

Drugs

Lp(a) lowering compound, D-47, produced by Dr. K. Ogawa, a co-author of this paper, was used to study Lp(a) function. D-47 is a pharmaceutical formulation composition of solid dispersion containing the arginine salt of S-2E [(S)(+)-4-[(4-tert-Butylphenyl)-2-oxo-pyrrolidine-4-yl]methoxybenzoic acid] (5), with “soluplus®” (BSAF) as the water soluble polymer, in the ratio of one to two. The water solubility and oral absorption of S-2E were improved by this solid dispersion, D-47, which was prepared by solvent method as described below.

The mixture of S-2E arginine salt (30 g) and soluplus (60 g) was dissolved in methanol 250 ml at around 50°C and then evaporated the solvent under reduced pressure. Into the residue, ethyl ether 100 ml was added and then evaporated the solvent. The final residue in the vessel was scraped together and then dried under reduced pressure at room temperature to obtain the D-47 (88 g). The amorphous state of S-2E arginine salt in D-47 was confirmed by X-ray powder diffraction analysis and DSC analysis.

Animal

Eight male Lp(a) transgenic mice were divided into two groups, control (n=4) and treated groups (n=4). Lp(a) transgenic mice were kindly provided by R. Morishita, Osaka University, Japan (6-8). Because apo(a) is present only in humans, primates and hedgehogs, we used Lp(a) transgenic mice that were generated by crossing human apo(a) transgenic mice (7) and human ApoB transgenic mice (8) to test the drug effects. The mice had free access to water and standard chow (standard non-purified diet, Oriental Yeast, Tokyo, Japan). Mice in the treated group were added D-47(30 mg/kg/day) to the standard chow from 10 weeks (i.e. 2 weeks before surgery) until 4 weeks after surgery. The mice in the control group were treated standard chow which was added only soluplus without D-47. At 12 week, vascular injury was performed to both groups. The experiments were approved by the Ethical Committee for Animal Experiments of the Tokushima University Graduate School of Medicine.
Production of vascular injury

Vascular injury was induced in mice as described previously (9, 10). A straight spring wire (0.38 mm in diameter, No.C-SF-15-15, COOK) was inserted into the femoral artery and left in place for 1 minute to denude and dilate the artery. Blood flow was restored. Artery was collected at day 28 after the injury. Mice were sacrificed by deep anesthesia and blood was sampled for analysis of lipid profile. For morphometric analysis, the femoral arteries were harvested at 4 weeks after the injury. To investigate the degree of neointimal formation, the proximal segments of the injured arteries were fixed in paraformaldehyde, embedded in paraffin, sectioned at 5 μm thickness, and stained with Elastica van Gieson. Neointima and media areas were measured by a computer-assisted image analyzer using Image J Software (BioArts).

Measurement of Lipid profile

Lp(a) was measured by latex agglutination turbidimetry using a commercial kit (COBAS MIRA, Sanwakagaku Co. Japan). Total cholesterol was measured by Ultra. Violet-End (UV-End) method using cholesterol dehydrogenase, and triglyceride was measured by enzymatic determination using the enzyme glycerol phosphate oxidase (GPO) after hydrolysis by lipoprotein lipase.

Statistics

The results were expressed as the mean± standard deviations. The data were compared two groups using Student’s t-test. As Lp(a) levels were variable in each animal, we also used nonparametric comparison (Mann-Whitney U test) between two groups. Values of P<0.05 were considered statistically significant.

RESULTS

Fig 1 shows the change of the lipid profile and blood glucose levels by the D-47. Treatment of the drug markedly reduced the blood levels of Lp(a) (30.3±12.7 mg/dL in the control group vs 5.5±1.3 mg/dL in the treated group, p=0.047 in U-test), and triglyceride (514.0±34.2 mg/dL vs 385.5±29.3 mg/dL, p=0.003). Blood levels of total cholesterol were not altered significantly by D-47 (279.0±20.1 mg/dL vs 284.0±15.3 mg/dL, p=0.721). Blood glucose levels were not different between two groups, either (251.7±47.4 mg/dL vs 327.5±64.7 mg/dL, p=0.149).

DISCUSSION

Lp(a) have been thought to be a cardiovascular risk factor. This study demonstrated that a novel Lp(a) lowering drug, D-47, successfully decreased plasma levels of Lp(a) and possibly inhibited neointima formation in Lp(a) transgenic mice. The results indicate that we can modulate plasma Lp(a) levels by pharmacologic agents and inhibit atherogenic properties by reducing plasma levels of Lp(a).

Lp(a) is a low density lipoprotein (LDL) particle which is attached to the polypeptide, apo(a). Apo(a) has unique structural properties, i.e., plasminogen kringles-4-like repeats (1,2). Because of the high degree of homology between apo(a) and plasminogen, Lp(a)/apo(a) can competitively inhibit tissue-type plasminogen activator-mediated plasminogen activation on fibrin surfaces, although the mechanism of inhibition by apolipoprotein(a) remains controversial. Lp(a) and apo(a) also have been thought to enhance the proliferation of human vascular smooth muscle cells (VSMCs) by inhibiting the activation of plasminogen to plasmin (11, 12). Further mechanisms have been shown to involve atherogeneity of this lipoprotein.

Lipoprotein apheresis is very efficient in decreasing Lp(a) concentrations. A single apheresis session can acutely decrease Lp(a) by approximately 60-75% and weekly or biweekly performed apheresis results in considerably decreased Lp(a) concentrations. In longitudinal cohort study, Jaeger BR et al. (13) showed combined lipoprotein apheresis and lipid-lowering medication prevent major adverse coronary events more efficaciously than lipid-lowering medication alone. Similarly, the Pro(a)LiFe-study confirmed with a prospective multicenter design that lipoprotein apheresis can effectively reduce Lp(a) plasma levels and prevent cardiovascular events (14). Ezhov MV et al. (15) also showed that isolated extracorporeal Lp(a) elimination over an 18 months period produced regression of carotid intima-media thickness in stable CHD patients with high Lp(a) levels. Although lipoprotein apheresis also decreases other atherogenic lipoproteins, such as oxidized LDL, these results suggest possibilities that lowering Lp(a) levels might reduce adverse coronary events.

Lp(a) is not present in experimental animal and Lp(a) is composed of a moiety with apolipoprotein B-100 (ApoB-100). Expression of apo(a) alone in mice does not form a complex with endogenous mouse LDL, indicating that human LDL is also required to study its function. Therefore, we have to use double transgenic mice with human apo(a) and human LDL to test the Lp(a) function. The previous studies showed that mice expressing the apo(a) gene developed atherosclerosis (16, 17). Using this model animal, Kyutoku M et al. (18) reported that DNA vaccine against apo(a) could significantly inhibit neointima formation in carotid artery ligation and concluded that the pro-atherosclerotic actions of Lp(a) could be prevented by reducing Lp(a) levels.

More recently, Evolocumb, a monoclonal antibody (mAb) to proprotein convertase subtilisin/kexin type 9 (PCSK9), decreases Lp(a) (19). The reduction of Lp(a) levels are thought to be secondary to low circulating LDL due to the increased LDL receptors by this drug.
Unfortunately, the high degree of homology between apo(a) and plasminogen has been difficult in the development of drugs against Lp(a). The drugs which selectively inhibit Lp(a) is particularly attractive to clinical application. D-47 is a novel drug which selectively lowers serum Lp(a) levels. Vascular injury model is a useful tools for investigating the mechanism of vascular remodeling because they involve leukocyte adhesion and infiltration, proliferation of smooth muscle cells and neointima formation (9, 10). Using this model and the double transgenic mice, we have shown that D-47 lowered serum levels of Lp(a) and possibly reduced vascular inflammation and neointima formation after vascular injury. Together with previous studies, the results of the present study suggest lowering of Lp(a) might reduce cardiovascular diseases related to high Lp(a).

This is a preliminary study of a new drug and the numbers of the studied animals were small, by which we could not obtain the statistical significance in reduction of neointima formation. Furthermore, the study was tested in model animals which are not identical to human. Therefore, we do not know whether we can extrapolate the results of the study to human with high Lp(a) levels. Further studies will be waited. The results of this study, however, suggest a novel therapeutic strategy for the treatment of cardiovascular diseases that are related to high Lp(a) levels.

ACKNOWLEDGEMENT

This study was supported in part by grants-in-aid from Adaptable and Seamless Technology transfer Program through target-driven R&D (# AS24Z02091Q).

DISCLOSURE

There are no conflicts of interest on D-47 and Lp(a).

REFERENCES

transgenic mice expressing human apolipoprotein (a). Nature 360 : 670-672, 1992
15. Ezhov MV, Safarova MS, Afanasieva OI, Pogorelova OA, Tripoten MI, Adamova IV, Konovalov GA, Balakhonova TV, Pokrovsky SN : Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels. Atheroscler 18(Suppl.) : 163-9, 2015